Health+Benefits the May 2010 issue

Medicare Tax Subsidy Cut

Will hit public company earnings in 2013.
By Scott Sinder Posted on May 1, 2010

For-profit companies currently receive a non-taxable RDS subsidy averaging more than $650 per plan member. Beginning in 2013, under the new law, the tax-free component of the RDS subsidy is eliminated.

For-profit employers that continue to offer the benefit and receive the subsidy, will have to pay hundreds in additional taxes for each participant. This change will have an immediate impact on publicly traded companies that opt to continue the program. Under Financial Accounting Standard 106, companies are required to report the net present value of their projected retiree expenses and to account for any change in the projected amount immediately. Therefore, the elimination of the tax-exempt treatment for the subsidy will have an immediate, detrimental impact on reported earnings of any publicly traded company that intends to continue the program after the tax change.  

Scott Sinder Chief Legal Officer, The Council; Partner, Steptoe Read More

More in Health+Benefits

Moving Backward on Biodefense?
Health+Benefits Moving Backward on Biodefense?
Though the Trump administration maintains it is committed to disease preparednes...
Health+Benefits Trump Administration Proposes 2026 Health and Human Services Budget
The full HHS budget for fiscal year 2026 would be more than $30 billion less tha...
The Great Good Place
Health+Benefits The Great Good Place
Q&A with Jennifer Finlay, Institute of Behavioral Science fellow, University of ...
Healthcare Providers Stay the Course on Vaccines
Health+Benefits Healthcare Providers Stay the Course on Vaccines
Q&A with Shawn Gremminger, President and CEO, National Alliance of Healthcare Pu...
ICHRAs Might Actually Be the Future
Health+Benefits ICHRAs Might Actually Be the Future
The case for employers to offer individual coverage health r...
Same Treatments, Dramatically Different Costs
Health+Benefits Same Treatments, Dramatically Different Costs
Q&A with Allison Oakes, Chief Research Officer, Trilliant He...